Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -3.27% | 138.47 | 0.7% | $830.15m | |
| PFE | Pfizer Inc. | -5.30% | 35.45 | 0.9% | $789.81m | |
| MRK | Merck & Co., Inc. | -2.31% | 76.19 | 0.7% | $626.60m | |
| BMY | Bristol-Myers Squibb Co. | -1.65% | 57.77 | 1.0% | $567.37m | |
| ABBV | AbbVie, Inc. | -2.68% | 80.49 | 1.9% | $557.75m | |
| LLY | Eli Lilly & Co. | -0.48% | 131.27 | 1.1% | $494.66m | |
| AZN | AstraZeneca Plc | -2.86% | 50.98 | 1.2% | $206.87m | |
| GSK | GlaxoSmithKline Plc | -3.93% | 33.96 | 0.2% | $147.19m | |
| NVS | Novartis AG | -3.25% | 78.32 | 0.2% | $140.00m | |
| NVO | Novo Nordisk A/S | -2.06% | 66.55 | 0.1% | $67.40m | |
| RGEN | Repligen Corp. | -2.64% | 171.20 | 7.1% | $64.29m | |
| RPRX | Royalty Pharma Plc | -4.62% | 36.12 | 0.2% | $59.77m | |
| TPTX | Turning Point Therapeutics, Inc. | 4.34% | 104.42 | 0.0% | $56.83m | |
| AMAG | AMAG Pharmaceuticals, Inc. | 0.07% | 13.71 | 22.1% | $46.96m | |
| SNY | Sanofi | -2.66% | 46.14 | 0.2% | $46.38m |
Company Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.